The control of latent cytomegalovirus (CMV) infections by the immune system is poorly understood. We have previously shown that CD4 ؉ T cells specific for the human CMV major regulatory protein IE1 are frequent in latently infected healthy blood donors. In order to learn about the possible role of these cells, we have developed IE1-specific CD4 ؉ T-cell clones and, in this study, analyzed their epitope specificity and function in vitro. We measured their cytokine production when stimulated with specific IE1 peptides or whole recombinant IE1 protein. Their cytokine profiles, as deduced from gamma interferon (IFN-␥), tumor necrosis factor alpha (TNF-␣), and interleukin-4 (IL-4) and IL-6 production, were of the Th0-and Th1-like phenotypes. Supernatants from IE1-specific clones producing IFN-␥ and TNF-␣ were shown to inhibit CMV replication in U373 MG cells. This effect was due, as found by using cytokine-specific neutralizing antibodies, mostly to IFN-␥, which was secreted at higher levels than TNF-␣. To better assess the anti-CMV activity of cytokines, recombinant IFN-␥ and TNF-␣ were used and shown to have a synergistic effect on the inhibition of CMV replication and protein expression. Thus, IE1-specific CD4 ؉ T cells display in vitro anti-CMV activity through cytokine secretion and may play a role in the control of in vivo latent infections.
Infections by human cytomegalovirus (HCMV), a beta-herpesvirus, are most often unnoticed in the immunocompetent host. Virus remains in a latent state and is reactivated in immunosuppressed patients undergoing transplantation or with pathologies such as cancer and AIDS (reviewed in reference 1). The control of CMV infection involves different compartments of the immune system. Cytotoxic CD8 ϩ T cells have been suggested as important effectors of the anti-HCMV response (31) and are mostly directed against matrix proteins, such as pp65 (14) . Antibodies directed against the envelope glycoprotein gB are markers of infection and neutralize the virus in vitro (25, 32) . In mice, CD4 ϩ T cells have been shown to participate in the clearing of CMV from salivary glands (24) . Human CD4 ϩ T cells specific for IE1, the major regulatory immediate-early protein, have been described (2) , and we have reported that the proportion of normal blood donors with anti-IE1 CD4 ϩ T-cell response is high (6) . CD4 ϩ T cells play a role in the defense against intracellular pathogens (18, 33) . Their participation in responses to viral infections, through the secretion of cytokines such as gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣), cytotoxicity, or help to B cells and CD8 ϩ cells is debatable (5, 9, 34) . The high precursor frequency of anti-IE1 CD4 ϩ T cells found in healthy HCMVpositive donors (6) suggested a potential role for these cells in the control of the latent virus. However, their functional characteristics have not been studied so far.
To understand cellular immunity against HCMV better, we have cloned IE1-specific CD4 ϩ T cells and examined their epitope specificity, cytokine production, and in vitro anti-HCMV activity. Using supernatant from these clones and recombinant cytokines, we have determined that IFN-␥ and TNF-␣ are important mediators of the anti-HCMV response in vitro.
MATERIALS AND METHODS
Virus and cell lines. CMV (Towne strain) was a kind gift from S. Michelson (Institut Pasteur, Paris, France). Virus stocks were obtained by infection of MRC5 cells (BioMérieux) at a multiplicity of infection (MOI) of 0.01 in BME with 10% fetal calf serum (FCS) supplemented with L-glutamine, sodium pyruvate, and antibiotics. CMV titers were measured on MRC5 cells. U373 MG cells (designated A0) were a kind gift from S. Michelson. IE-transfected U373 MG cells (designated A2) were a kind gift from R. LaFemina (Merck, Sharpe, and Dome, West Point, Pa.). IE1-transfected U373 MG cells (A1b) have been described previously (6) .
Reagents and antibodies. E13, an immunoglobulin G1 (IgG1) mouse monoclonal antibody (MAb) specific for IE proteins, was a kind gift from M.-C. Mazeron (Hôpital Lariboisière, Paris, France). MAb CCH2 (anti-early protein) and 1201 (anti-gB), both murine IgG1 MAbs, were purchased from DAKO and the Goodwin Institute (Plantation, Fla.), respectively. The isotype control IgG1 was from Meloy. Phycoerythrin (PE)-coupled F(abЈ)2 goat anti-mouse IgG plus IgM antiserum was purchased from Immunotech. Anti-IFN-␥, a mouse IgG2a MAb, and anti-TNF-␣ goat antisera were obtained from Boehringer and R & D Systems, respectively. Synthetic 20-mer peptides, overlapping by 5 residues, spanning the IE1 (86 to 257) region were purchased from Chiron Mimotopes. Peptide IE1 (158 to 175) was a kind gift of Jean-Edouard Gairin (Centre National de la Recherche Scientifique, Toulouse, France).
Flow cytometry. A0 cells were incubated with various amounts of recombinant IFN-␥ (rIFN-␥), rTNF-␣, or both for 24 h. The cytokines were then removed, and HCMV (MOI of 2 for MAb E13 and CCH2 staining, MOI of 75 for gB staining) was added and left in the cultures for 20 h. The virus inoculum was then replaced with fresh RPMI-FCS medium until cell harvest at the times indicated below.
The expression of HCMV proteins was determined by flow cytometry. A0 cells were harvested with Versene (Gibco), centrifuged once in RPMI-FCS medium, once in Mg 2ϩ -and Ca 2ϩ -free phosphate-buffered saline (PBS), and resuspended in 200 l of PBS. Cells were fixed by addition of 1.8 ml of Ϫ20ЊC methanol and kept at Ϫ20ЊC for at least 1 h. Fixation for up to 10 days did not alter the pattern of immunofluorescence. Cells were then centrifuged once with PBS and once in PBS-XA (PBS supplemented with 0.002% Triton X-100, 0.5% bovine serum albumin [BSA] , 0.1% NaN 3 ). One hundred microliters of PBS supplemented with 0.002% Triton X-100, 25% NGS (Gibco), and 0.1% NaN 3 was added to the pellets, and cells were incubated for 30 min at 37ЊC. This step was followed by 1 h of incubation at 37ЊC in the presence of control isotype IgG1 or specific antibody (1 g per sample). Samples were washed twice in PBS-XA and incubated with PE-labeled antiserum for 30 min at 37ЊC. Samples were analyzed with a Coulter EPICS Elite cell sorter.
Peptide specificity of anti-IE1 CD4 ؉ T-cell clones. CD4 ϩ T-cell clones specific for IE1 were obtained from healthy seropositive blood donors as previously described (8) . Recombinant interleukin-2 (IL-2) (20 U/ml) was either present from the beginning of the primary culture (clones FzB1, FzD3, and FzF12.2), added on day 2 (clone BeA3), or added on day 7 (clones FzA6, FzD11, LaB5, and LaC4). The clones were cultured in RPMI-Glutamax supplemented with 1 mM sodium pyruvate, 200 U of penicillin per ml, 80 g of streptomycin per ml, and 10% human serum from pooled blood (RPMI-HS). Restimulations were performed every 7 to 10 days with either allogeneic irradiated peripheral blood mononuclear cells (PBMC) in the presence of phytohemagglutinin (PHA; 1 g/ml) and recombinant IL-2 (20 U/ml) (Sanofi, Labège, France) or HLAmatched PBMC and specific peptide plus recombinant IL-2 (20 U/ml).
T-cell clone proliferation assays were performed in triplicate in 96-well microtiter plates (Falcon) in a final volume of 100 l of RPMI-HS as follows. Cells (2 ϫ 10 4 per well) were cultured in the presence of 10 5 irradiated HLA-matched PBMC plus peptide (1 g/ml) for 72 h. Tritiated thymidine (1 Ci/well) was added for an additional 16 h. Cells were harvested, and incorporated thymidine was measured on a beta counter.
Cytokine production by PBMC and anti-IE1 CD4 ؉ T-cell clones. PBMC were cultured in RPMI-HS. PBMC (10 5 per well, in triplicate) from CMV-positive healthy blood donors were cultured in microtiter plates for 24 h in the presence of PHA, for 5 days in the presence of total CMV antigens (Ags), and for 5 to 7 days in the presence of IE1 or the control. Supernatants were collected, and triplicates were pooled and stored at Ϫ80ЊC until cytokine determination. IE1 Ag was a lysate of IE1-transfected astrocytoma cells (A1b). Total HCMV Ags were a lysate of infected astrocytoma cells (A0inf). Control Ag was a lysate of untransfected, noninfected astrocytoma cells (A0).
T-cell clone stimulations for cytokine production were performed in 96-well microtiter plates (Falcon) in 100 l of RPMI-HS as follows. Cells (2 ϫ 10 4 ) were incubated in the presence of 10 5 irradiated HLA-matched Epstein-Barr virus (EBV)-transformed B cells plus peptide (10 g/ml) or an appropriate dilution of IE Ag (from IE-transfected A2 cells) (6) . Supernatants of clones cultured either in the absence of peptide or in the presence of A0 cell lysate were used as controls. Supernatants were collected after 20 h of incubation and stored at Ϫ80ЊC until cytokine determination by enzyme-linked immunosorbent assay (ELISA). IFN-␥ and IL-4 concentrations were measured with the Medgenix Screening Line. TNF-␣ not coupled to the soluble receptor was measured with an ELISA kit from Innogenetics. IL-6 was measured with a kit from Immunotech.
Plaque reduction assay. Plaque reduction assays were done with either recombinant cytokines or T-cell clone supernatants. MRC5 cells were incubated with various amounts of rIFN-␥, rTNF-␣, or both for 24 h. The cytokines were then removed, various dilutions of HCMV (titer, 10 6 PFU/ml) were distributed into the wells, and plaques were counted after 7 to 10 days of infection. In other experiments, 1:10-diluted T-cell clone supernatant was left untreated or incubated in the presence of either anti-IFN-␥ (10 g/ml), anti-TNF-␣ (10 g/ml), or anti-IFN-␥ plus anti-TNF-␣ (10 g/ml each) for 1 h at room temperature in 24-well culture plates. As a control, MRC5 cells were incubated with mouse IgG2a specific for human Ig lambda light chain (Caltag) and normal goat serum. MRC5 cells (half-confluent) were then added to the wells and incubated for 24 h. The medium was removed, various dilutions of HCMV were distributed in the wells, and plaques were counted after 7 to 10 days of infection.
Inhibition of HCMV production. A0 cells (2 ϫ 10 5 cells per well) were seeded in 24-well plates (Nunc). Cells from the IE1-specific BeA3 clone (1.5 ϫ 10 4 cells) were placed above in 10-mm insert culture dishes (0.45-m polycarbonate membrane; Nunc) and incubated in the presence of 5 ϫ 10 5 irradiated HLA-matched EBV-transformed B cells and in the presence or absence of specific peptide (10 g/ml) for 3 days in RPMI-10% FCS (RPMI-FCS). The inserts were then discarded, A0 cells were incubated with HCMV (MOI of 5) for 2 h, and the inoculum was removed and replaced with fresh RPMI-FCS. After 5 days of infection, the wells were washed three times with culture medium, and A0 cells were detached with Versene (Gibco) and lysed by sonication. The HCMV titer was measured on MRC5 cells.
Alternatively, IE1-specific clone FzD11 (2 ϫ 10 4 cells per well) was specifically stimulated in the presence of 5 ϫ 10 4 HLA-matched EBV-transformed B cells and specific peptide (10 g/ml) in RPMI-FCS medium. Supernatant was collected 20 h later and incubated with A0 cells (4 ϫ 10 5 cells per well) in six-well plates for 24 h. As a control, A0 cells were cultured for 24 h in the absence of supernatant. A0 cells were then infected (MOI of 5) for 5 days. The wells were then washed three times with culture medium, and A0 cells were detached with Versene and lysed by sonication. The HCMV titer was measured on MRC5 cells.
In other experiments, A0 cells were incubated with various amounts of rIFN-␥, rTNF-␣, or both for 24 h. The cytokines were then removed, and the cells were incubated with HCMV overnight (MOI of 1). The inoculum was then aspirated. After 7 days of infection, the cells were detached with Versene and lysed by sonication. The virus titer was measured on MRC5 cells.
RESULTS
Production of IFN-␥ by specifically activated PBMC from HCMV-positive blood donors. We first performed short-term culture assays of PBMC in the presence of HCMV Ags and evaluated IFN-␥ production. Table 1 shows that PBMC secreted high amounts of IFN-␥ after 5 to 7 days of culture in the presence of IE1 Ag or total HCMV Ags compared with 24 h of stimulation with PHA. As previously reported regarding pri- a PBMC from HCMV-positive blood donors (Be, Fz, and La) were cultured in the presence of HCMV antigens obtained from lysates of astrocytoma cells either transfected with the IE1 gene (A1b) or infected with HCMV Towne (A0inf). The polyclonal mitogen PHA was used as a positive control. Supernatants were collected and tested for IFN-␥ by ELISA after 5 to 7 days of culture (stimulation with IE1 and total Ags) or 24 h (culture in the presence of PHA). Background production by PBMC cultured in the same experiment in the presence of a lysate of untreated A0 cells was 50 pg/ml (Be), 260 pg/ml (Fz), and undetectable (La) and was subtracted from the values obtained after stimulation with PHA or HCMV Ags. Detailed analysis of this epitope will be published separately (12a). The epitopes recognized by FzA6 and LaC4 were not determined by using the IE1 (86 to 257) overlapping peptides and remain to be identified within the sequence encoded by exon 4. Cytokine production by anti-IE1 CD4 ؉ T-cell clones. Eight CD4 ϩ T-cell clones were tested for cytokine production. As shown in Table 2 , all the clones tested produced IFN-␥, and only one (FzA6) did not produce TNF-␣. Three clones (FzA6, FzF12.2, and LaC4) did not produce IL-4; of these, two (FzF12.2 and LaC4) produced lower amounts of IFN-␥ than the other clones, and one did not produce TNF-␣ either (FzA6). Th2-type cytokine IL-6 could not be detected in supernatants. Therefore, anti-IE1-specific clones exhibited a Th0-and Th1-like profile of cytokine production (34) . The cytokine profiles were independent of the presence of rIL-2 at the beginning of the primary culture (see Materials and Methods).
Inhibition of HCMV production and plaque reduction by anti-IE1 CD4
؉ T-cell clones. We next studied whether anti-IE1 CD4
ϩ T-cell clones displayed anti-HCMV activity in vitro. Two types of experiments were performed. First ( Fig. 2A) , when clone BeA3 was incubated with A0 cells and HLAmatched antigen-presenting cells (APC) in the presence of specific IE1 peptide prior to infection, HCMV production was reduced to undetectable levels in comparison with the control preincubation performed in the absence of peptide. In the other experiment (Fig. 2B) , undiluted supernatant of specifically activated clone FzD11 was incubated with A0 cells. Again, HCMV production by A0 was markedly decreased compared with the control supernatant.
In order to assess which cytokines were responsible for the anti-HCMV activity of the clones, 1:10-diluted supernatants were incubated with anti-IFN-␥, anti-TNF-␣, or both. The results, displayed in Fig. 3 , showed drastic inhibition of the number of PFU by T-cell clone supernatant compared with that from MRC5 cells not incubated with supernatant. The PFU were smaller, as indicated by asterisks. As expected, control Abs did not restore the number of PFU, which remained small. Anti-TNF-␣ induced only a twofold increase in the number of PFU compared with control Abs, and the PFU were also smaller in this group. IFN-␥ produced by the anti-IE1 CD4 Staining with CCH2 at day 2 p.i. showed barely detectable early protein (results not shown). Early protein expression was analyzed at day 5 p.i. with CCH2 MAb (Fig. 5A) . Mean fluorescence intensity could be used to measure protein expression, since, contrary to IE expression, the fluorescence pattern given by CCH2 showed a unimodal bell-shaped curve (not shown). rIFN-␥ had a strong inhibitory effect on early protein expression that was more pronounced than with rTNF-␣. When used together, rIFN-␥ and rTNF-␣ had a synergistic effect which was observed at concentrations of 50, 500, and 5,000 pg of each cytokine per ml. Figure 5B shows that results on the inhibition of gB expression by rIFN-␥ and rTNF-␣ were similar to that obtained with MAb CCH2.
Plaque reduction and inhibition of HCMV production by rIFN-␥ and rTNF-␣. To test whether concentrations of recombinant cytokines similar to those found in the supernatants of activated anti-IE1 CD4 ϩ clones could inhibit virus replication and assembly, we analyzed PFU inhibition on MRC5 cells. Figure 6A shows that rIFN-␥ and rTNF-␣ used separately induced only a slight dose-dependent PFU reduction. However, the combination of rIFN-␥ and rTNF-␣ was effective, since a strong synergistic effect was observed; the number of PFU was reduced 100-fold. A different pattern on virus production by A0 cells was observed (Fig. 6B) : rIFN-␥ and rTNF-␣ almost equally reduced HCMV production in a dose-dependent fashion. The inhibition of production by each cytokine was sub- 
DISCUSSION
We have shown in this study that IE1-specific CD4 ϩ T-cell clones display anti-HCMV activity in vitro. It is clear from our results that specific activation induces the production of IFN-␥ and TNF-␣ by anti-IE1 CD4 ϩ clones whose supernatants are active on HCMV in vitro. Recombinant IFN-␥ and TNF-␣ possess anti-HCMV activity in vitro. These cytokines could play a role as effectors of the specific CD4 ϩ anti-HCMV IE1 response, which is a significant component of the total anti-HCMV response (6) .
Flow cytometry analysis of HCMV protein expression provided an accurate and reproducible evaluation of cytokine activity on infected A0 cells. The effect on HCMV protein expression correlated well with the reduction in virus production by A0 cells. Since flow cytometry analyzes cells individually, our data indicate that the reduction of virus replication could not be attributed to a decrease in the total number of cells but to a reduction of the infection on a per-cell basis after incubation with rIFN-␥ and rTNF-␣. Therefore, flow cytometry is a good indicator of virus replication in A0 cells in vitro. The existence of two different populations with regard to IE inhibition was consistently observed and was not dependent on the time of IE staining postinfection (data not shown). Half of the A0 cells could be more sensitive to rIFN-␥ and rTNF-␣ action on IE expression, depending on their cell cycle phase at the beginning of the infection, for example. Alternatively, this staining pattern may be due to the expression of different IE proteins by separate cells after incubation with rIFN-␥ and rTNF-␣, since MAb E13 recognizes several IE proteins (26) . It thus appears that inhibition of HCMV replication by IFN-␥ and TNF-␣ does not occur, at least for a population of cells, in the IE phase. Our data are in agreement with a previous study which also showed that rIFN-␥ only moderately inhibited IE expression in human fibroblasts (39) . Another report showed in a murine model that rIFN-␥ and rTNF-␣ induced a latephase inhibition of CMV replication (23) . Inhibition of early and late protein expression by rIFN-␥ and rTNF-␣ was assessed, in our experiments, in the late phase of infection. Further experiments are needed to determine whether the early or late phase is the target of rIFN-␥ and rTNF-␣ effects on HCMV replication. In this study, cells with different kinetics of virus replication, A0 and MRC5, were used. This shows that the anti-HCMV effects of cytokines were not limited to the cell type. Surprisingly, treatment of anti-IE1 clone supernatants with neutralizing Abs showed a role for IFN-␥ but not for TNF-␣ in anti-HCMV activity. This could be due to the fact that inactivation of TNF-␣ by Abs was masked by the effects of IFN-␥, which is secreted in higher amounts. However, TNF-␣ secreted by IE1-specific T cells may participate in the anti-HCMV response when associated with TNF-␣ released by IFN-␥-activated macrophages (40) . A cytokine(s) other than IFN-␥ and TNF-␣ produced by IE1-specific CD4 ϩ T cells may also inhibit CMV replication since the combination of anti-IFN-␥ and anti-TNF-␣ did not completely inactivate the anti-CMV effect of the T-cell clone culture supernatant.
Cross-regulations of CMV infection and TNF-␣ production have been reported: TNF-␣ has been shown to stimulate the activity of the IE promoter in immature monocytic cells, whereas it inhibited IE in mature cells (37) . On the other hand, HCMV infection (36) and IE expression (13) have been shown to upregulate TNF-␣ gene expression in the monocytic cell line THP-1, thereby potentially involving TNF-␣ in the inflammatory response associated with HCMV infections. Anti-IE1 CD4 ϩ T-cell-derived TNF-␣ may play such a role as a local factor of inflammation. TNF-␣ has also been described to activate human immunodeficiency virus (HIV) in vitro (16) . This represents yet another example of the multiple effects of TNF-␣, depending probably both on the cell target and on the virus itself. Our results suggest that the anti-HCMV immune response may play a detrimental role in HIV infection through TNF-␣ production. CD4 ϩ T cells have been shown to control, partly via cytokines, murine CMV infections (15, 17) in vivo and have been suggested to take part in anti-virus protective immunity in humans (34) . Human IFN-␥ and TNF-␣ have been previously reported as cytokines with antiviral activity in vitro (11, 28, 43) . The previously reported human Th1-type clones specific for hepatitis B virus (3) and varicella-zoster virus (45), Th0-type clones specific for HSV (44) , and Th0 specific for Toxoplasma gondii (29) suggested a role for cytokines secreted by CD4 ϩ T cells in human viral and parasitic infections. However, few papers have analyzed the cytokine production by panels of CD4 ϩ T-cell clones specific for viral proteins (12, 22, 35) . The functional characteristics of anti-IE1 CD4 ϩ clones were of the Th0 and Th1 phenotype, since some produced IFN-␥ but no IL-4 and some produced both IL-4 and IFN-␥. An in vitro bias towards the Th0-Th1 phenotype cannot totally be excluded. However, since the addition rIL-2 in the first days of the generation of clones was not related to a particular cytokine profile, it is unlikely that such a bias has occurred. In addition, it is obvious that PBMC from the HCMV-positive blood do- nors from whom the clones were derived produced high amounts of IFN-␥ after stimulation with recombinant IE1 protein. Soluble IE1 has been shown to activate CD4 ϩ T cells in vitro (6) . Therefore, our anti-IE1 CD4 ϩ clones are not likely to represent a minor population of CD4 ϩ cells selected by in vitro conditions.
The epitope described in the present paper for HLA-DR3 presentation overlaps that described after proliferation assays of a T-cell line from a CMV-positive donor in the presence of synthetic peptides (2) . The peptide recognized by BeA3, an HLA DR8-restricted clone, was also described in reference 2 for the response of a cytotoxic T-cell line from a CMV-positive donor. This observation, along with the demonstration that DR13-restricted clone LaB5 recognizes a peptide overlapping the DR3-restricted FzD11 epitope, suggests that a limited number of peptides could be responsible for IE1-specific T-cell response. In addition, we have shown that substitutions of residues in the BeA3 clone epitope enhance functional response (12a) and that the combination of the GST-e4-encoded portion of IE1 with synthetic biovectors also potentiates IE1-specific clonal CD4 ϩ T-cell response (29) . These data could be of interest in developing subunit vaccines.
This panel of anti-IE1 CD4 ϩ T-cell clones, although limited in number, is in favor of an effective anti-HCMV response by IE1-specific CD4 ϩ cells through the local release of factors. The variability of the cytokine response of the different clones may reflect the heterogeneity of the total CD4 ϩ anti-IE1 response. However, the consistent observation of IFN-␥ production by anti-IE1 clones suggests functional significance. The high frequency and in vitro function of IE1-specific CD4 ϩ T cells (6) is in contrast to IE1-specific CD8 ϩ T cells, whose action seems to be limited by low precursor frequency and poor activity in vitro on infected cells (14) . IE1-specific CD4 ϩ T cells may also participate in the regulation of HCMV latent infection through help to cytotoxic CD8 ϩ T cells directed against proteins other than IE1 (14) . A0 cells and MRC5 cells, which do not spontaneously express class II antigens (7), are shown here as an example of bystander infected cells. Coculture of latently infected granulocyte-macrophage progenitors with bystander fibroblasts can lead to HCMV reactivation (19) . We speculate that during reactivation of latent infection in monocytes/macrophages under various factors (38) , anti-IE1 CD4 ϩ cells activated upon reexpression and presentation of IE1 protein would promptly release factors which prevent the slow process of HCMV infection in neighboring cells. Other mechanisms, such as induction of major histocompatibility complex (MHC) class II expression on bystander cells (7, 41) , direct cytotoxicity (21) , and prevention of MHC class I downregulation by infected cells (4, 42) , may also contribute to an effective immune response.
